Protein Kinase Inhibitors: all 15,278 studies that test it
Page 98 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.
- Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal CancerStatus unknownNCT04008511Phase 1/2
- Cobimetinib for BRAF-wild-type or Mutated HistiocytosesCompletedNCT04007848Phase 3
- Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKIStatus unknownNCT04007835Not applicable
- A Food-Effect Study of SHC014748M in Healthy SubjectsStatus unknownNCT04006860Phase 1
- PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric AdenocarcinomaStatus unknownNCT04006821Phase 2
- Entacapone Combination With Imatinib for Treatment of GISTCompletedNCT04006769Early Phase 1
- Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung CancerTerminatedNCT04005144Phase 1
- Clinical Study on the Treatment of Recurrent Glioblastoma With AnlotinibStatus unknownNCT04004975Phase 1/2
- Bioavailability Study of PF-06651600 Formulations in Healthy ParticipantsCompletedNCT04004663Phase 1
- A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationActive, not recruitingNCT04002297Phase 3
- Anlotinib in Metastatic HER2 Negative Breast CancerCompletedNCT04002284Phase 2
- YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)CompletedNCT04000737Phase 2
- Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian CancerStatus unknownNCT04000295Phase 3
- Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLCStatus unknownNCT03998085Not applicable
- A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerStatus unknownNCT03997539Phase 2
- Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCActive, not recruitingNCT03997123Phase 3
- Genetic Testing in Guiding Treatment for Patients With Brain MetastasesActive, not recruitingNCT03994796Phase 2
- Study of Dosage Exploration and Pharmacokinetics for HA121-28 TabletsStatus unknownNCT03994484Phase 1
- Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in METActive, not recruitingNCT03993873Phase 1
- Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung CancerActive, not recruitingNCT03991819Phase 1
- Fostamatinib in the Treatment of Chronic Active Antibody Mediated RejectionActive, not recruitingNCT03991780Phase 1/2
- Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLCTerminatedNCT03990077Phase 1
- Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic LeukemiaCompletedNCT03989466Phase 1
- A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast CancerWithdrawnNCT03988114Phase 4
- Treatment of Congenital Vascular Malformations Using Sirolimus: Improving Quality of LifeStatus unknownNCT03987152Phase 3
- Apatinib Plus SHR1210 in Advanced Mucosal MelanomaStatus unknownNCT03986515Phase 2
- Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT03985189Phase 1
- Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT03983824Phase 1
- Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult SubjectsCompletedNCT03983239Phase 1
- A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic ImpairmentCompletedNCT03983161Phase 1
- Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast CancerActive, not recruitingNCT03982485Phase 2
- A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerActive, not recruitingNCT03980054Phase 3
- Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)CompletedNCT03980041Phase 2
- Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast CancerTerminatedNCT03979508Phase 2
- A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy ParticipantsCompletedNCT03979248Phase 1
- Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal CancerStatus unknownNCT03977090Phase 1
- Phase I Study of HL-085 in Patients With Advanced Solid TumorsTerminatedNCT03976050Phase 1
- Pediatric Long-Term Follow-up and Rollover StudyActive, not recruitingNCT03975829Phase 4
- Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid CancerSuspendedNCT03975231Phase 1
- Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 AntibodyStatus unknownNCT03975036Phase 2/3
- Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's LymphomaCompletedNCT03974243Phase 1/2
- Study of HL-085 in NRAS Mutant Advanced MelanomaCompletedNCT03973151Phase 1/2
- NPC-12G Gel 0.2% Sirolimus PK Bridging StudyCompletedNCT03972462Phase 1
- Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT03972189Phase 2
- Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant MelanomaWithdrawnNCT03972046Phase 2
- Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerActive, not recruitingNCT03971409Phase 2
- A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular CarcinomaTerminatedNCT03970616Phase 1/2
- Whole Genomic Landscape of Advanced EGFR-mutant NSCLCActive, not recruitingNCT03969823Not applicable
- Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast CancerCompletedNCT03969121Phase 3
- Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid TumorsTerminatedNCT03968653Phase 1
- Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain MetastasesCompletedNCT03967522Phase 2
- A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerStatus unknownNCT03966898Phase 3
- AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing SurgeryTerminatedNCT03965494Early Phase 1
- Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)Active, not recruitingNCT03964090Phase 2
- A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy SubjectsCompletedNCT03964038Phase 1
- Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)CompletedNCT03963206Phase 4
- Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy ParticipantsCompletedNCT03961997Phase 1
- Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCLActive, not recruitingNCT03960840Phase 1/2
- A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy SubjectsCompletedNCT03958864Phase 1
- Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese SubjectsCompletedNCT03956953Phase 1
- Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.CompletedNCT03954782Phase 2
- Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric CancerStatus unknownNCT03954756Phase 2
- A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell LymphomaActive, not recruitingNCT03952078Phase 1
- Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell TransplantationTerminatedNCT03951961Phase 2
- The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia PatientsCompletedNCT03951623Phase 1
- Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue SarcomaCompletedNCT03951571Phase 2
- Study of FCN-437c in Patients With Advanced Solid TumorsCompletedNCT03951116Phase 1
- Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid TumorsActive, not recruitingNCT03950609Phase 2
- ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast CancerCompletedNCT03950570Phase 1/2
- Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric CancerStatus unknownNCT03950141Phase 2
- Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLStatus unknownNCT03949062Phase 2
- Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.Status unknownNCT03947242Not applicable
- Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic SarcomaStatus unknownNCT03946943Phase 2
- Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT03946878Phase 2
- A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery RecurrenceTerminatedNCT03945799Phase 1/2
- Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male SubjectsCompletedNCT03945760Early Phase 1
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBCCompletedNCT03945604Phase 1
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingNCT03944772Phase 2
- FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast CancerActive, not recruitingNCT03944434Phase 2
- Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)Status unknownNCT03943602Phase 2
- Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib ResistanceWithdrawnNCT03943342Phase 2
- The Efficacy and Safety of Sirolimus for Plastic BronchitisStatus unknownNCT03942926Phase 2
- Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal RevascularizationTerminatedNCT03942601Phase 2
- Nilotinib for First-line Newly Diagnosed CML-CP PatientsStatus unknownNCT03942094Phase 3
- Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT03942068Phase 2
- Study Evaluating the Mass Balance And Biotransformation of Single Dose[14C] AST2818 in Chinese Healthy Male VolunteersCompletedNCT03941340Phase 1
- Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)Status unknownNCT03940976Phase 2
- Management of Progressive Disease in Idiopathic Pulmonary FibrosisCompletedNCT03939520Phase 4
- Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell LymphomaCompletedNCT03939182Phase 1
- Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian CancerCompletedNCT03936270Phase 2
- Effect of Meal Composition and Timing on Evobrutinib BioavailabilityCompletedNCT03934502Phase 1
- A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast CancerStatus unknownNCT03933982Phase 2
- Effect of Nilotinib in Cerebellar Ataxia PatientsCompletedNCT03932669Phase 2
- Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast CancerStatus unknownNCT03932526Phase 2
- Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165CompletedNCT03930602Phase 1
- Anlotinib in Advanced Solid Tumors With FGFR AlterationStatus unknownNCT03929965Not applicable
- Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.CompletedNCT03929510Phase 1
- A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerStatus unknownNCT03927456Phase 3
- Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial HypertensionCompletedNCT03926793Phase 1
- Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male VolunteersCompletedNCT03926182Phase 1